Updated Jul 16, 2026
Rodman David Malcom has filed 7 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $5.99M.

David Malcom Rodman is the Chief Medical Officer at Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for diseases related to elevated aldosterone levels. He has been involved in multiple SEC filings related to his role at the company.
| Role | Chief Medical Officer |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-16 | MLYS | Mineralys Therapeutics, Inc. | S — Open-market sale [10b5-1] | 6.3K | $26.61 | $169K |
| 2026-07-16 | MLYS | Mineralys Therapeutics, Inc. | S — Open-market sale [10b5-1] | 14.1K | $27.58 | $388K |
| 2026-07-16 | MLYS | Mineralys Therapeutics, Inc. | M — Option exercise [10b5-1] | 6.3K | $1.08 | $7K |
| 2026-07-16 | MLYS | Mineralys Therapeutics, Inc. | M — Option exercise [10b5-1] | 4.2K | $14.25 | $59K |
| 2026-07-16 | MLYS | Mineralys Therapeutics, Inc. | M — Option exercise [10b5-1] | 3.5K | $10.20 | $36K |
| 2026-07-10 | MLYS | Mineralys Therapeutics, Inc. | S — Open-market sale | 2.2K | $30.30 | $66K |
| 2026-07-10 | MLYS | Mineralys Therapeutics, Inc. | M — Option exercise | 2.2K | $16.00 | $35K |
| 2026-06-18 | MLYS | Mineralys Therapeutics, Inc. | S — Open-market sale | 4.6K | $25.00 | $115K |
| 2026-06-18 | MLYS | Mineralys Therapeutics, Inc. | M — Option exercise | 417 | $15.44 | $6K |
| 2026-06-18 | MLYS | Mineralys Therapeutics, Inc. | M — Option exercise | 4.2K | $14.25 | $59K |
| 2026-06-18 | MLYS | Mineralys Therapeutics, Inc. | S — Open-market sale | 9.9K | $23.81 | $235K |
| 2026-06-18 | MLYS | Mineralys Therapeutics, Inc. | M — Option exercise | 3.5K | $10.20 | $36K |
| 2026-06-12 | MLYS | Mineralys Therapeutics, Inc. | S — Open-market sale | 6.3K | $23.93 | $152K |
| 2026-06-12 | MLYS | Mineralys Therapeutics, Inc. | M — Option exercise | 6.3K | $1.08 | $7K |
| 2026-06-12 | MLYS | Mineralys Therapeutics, Inc. | S — Open-market sale | 2.2K | $25.00 | $54K |
| 2026-06-12 | MLYS | Mineralys Therapeutics, Inc. | M — Option exercise | 2.2K | $16.00 | $35K |
| 2026-05-19 | MLYS | Mineralys Therapeutics, Inc. | S — Open-market sale | 417 | $27.55 | $11K |
| 2026-05-19 | MLYS | Mineralys Therapeutics, Inc. | M — Option exercise | 417 | $15.44 | $6K |
| 2026-05-14 | MLYS | Mineralys Therapeutics, Inc. | S — Open-market sale | 14.1K | $28.58 | $402K |
| 2026-05-14 | MLYS | Mineralys Therapeutics, Inc. | M — Option exercise | 4.2K | $14.25 | $59K |
David Malcom Rodman is the Chief Medical Officer at Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for diseases related to elevated aldosterone levels. He has been involved in multiple SEC filings related to his role at the company.…
7 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 38 open-market sales ($5.99M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Rodman David Malcom profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.